Dentist Busted: DEA Yanks License for Sketchy Drug Forms
Published Date: 2/14/2025
Notice
Summary
Dr. Robert L. Carter, a dentist from Delaware, lost his DEA license because he lied on his renewal forms and didn’t meet public safety standards. His new application to work in New Jersey was also denied, mainly because he lacks the proper state permission and has a history of falsifying documents. This means he can’t legally handle controlled substances in either state, affecting his dental practice and career starting now.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Dentist's DEA Registration Revoked
The DEA revoked Robert L. Carter's Certificate of Registration No. BC5574048 and denied his application No. W20128194C and any other pending application for registration in Delaware or New Jersey. The Order is effective March 17, 2025, and means Dr. Carter cannot legally hold a DEA registration to handle, prescribe, or dispense controlled substances in Delaware or New Jersey.
Falsified Applications and Unlawful Prescribing
The DEA found Dr. Carter materially falsified multiple DEA renewal applications (including false answers on renewals dated 2009, 2012, 2015, 2018, and 2021) and issued eight controlled-substance prescriptions on New Jersey prescription pads between June 19, 2019 and November 28, 2020 while his DEA registration was registered to Delaware. Those findings under 21 U.S.C. 824(a)(1) and 824(a)(4)/823(g) supported revocation and denial.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-02621 — Commercial Customs Operations Advisory Committee
The Commercial Customs Operations Advisory Committee (COAC) is meeting on March 5, 2025, in Atlanta, and anyone can join in person or online. This meeting affects businesses and travelers involved in customs, as they’ll hear updates and discuss improvements to customs operations. Space is limited for in-person attendees, so don’t wait to sign up if you want to join live!
Next: 2025-02624 — Certain Corrosion-Resistant Steel Products From the Republic of Korea: Notice of Court Decision Not in Harmony With the Results of Countervailing Duty Review; Notice of Amended Final Results
The U.S. Court of International Trade made a decision that changes the subsidy rates for certain corrosion-resistant steel products from Korea, affecting Dongbu Steel and its related companies. This means the government is updating the final results for the 2019 review, which could impact duties these companies pay. If you’re involved with these steel products, keep an eye on these new rates and deadlines!